AbbVie sees FY13 revenue $18.5B, consnesus $18.65B Expects R&D expense to be 15% of sales, SG&A expense to be 27% of sales. Sees FY13 effective tax rate of approximately 22%. Comments taken from Q3 earnings conference call.
News For ABBV From The Last 14 Days
Check below for free stories on ABBV the last two weeks.
AbbVie volatility at historic low as shares at record high AbbVie December and January call option implied volatility is at 20, May is at 22; below its 26-week average of 24 according to Track Data, suggesting decreasing price movement.